Clinical Value Screening, Prognostic Significance, and Key Gene Identification of TrkB in Laryngeal Carcinoma

Purpose Using human gene chip expression profiling technology to screen out downstream genes related to TrkB regulation in laryngeal cancer cells. Methods Using the Hep-2 TrkB shRNA cell line, divide it into an experimental group (shNTRK2) and a control group (PLKO1), and use the human gene expression microarray to screen out the differential genes. Then, select 10 upregulated genes and 10 downregulated genes from the differential genes, and use RT-PCR to verify whether the screening results of human gene expression microarray profiles are reliable. Use GO, KEGG, and miRNA enrichment analyses, PPI network diagram, etc., to analyze the differential genes and further screen out the key genes. Results A total of 318 differential genes (87 upregulated genes and 231 downregulated genes) were screened in laryngeal cancer cells. Use RT-PCR for the 10 upregulated differential genes (DMKN, FHL1, FOXN4, GGNBP1, HOXB9, ABCB1, TNFAI, RGS2, LINC01133, and FGG) and 10 downregulated differential genes (CHI3L1, FMOD, IGFBP1, IRF5, SPARC, NPAS4, TRPS1, TRAP, COL8A1, and DNER), and the results are consistent with the chip results, confirming the accuracy of the chip results; GO analysis results show that the downstream differential genes (DEGs) regulated by TrkB are mainly involved in biological processes such as retinol metabolic process, diterpenoid metabolic process, and regulation of cell-substrate adhesion. DEGs mainly affect cytoskeletal protein binding, serotonin-activated cation-selective channel activity, and sphingosine molecular functions. DEGs are mainly enriched in the cell periphery, secretory granule, cytoplasmic membrane-bounded vesicle lumen, blood microparticle, and other molecular components. The results of disease enrichment analysis show that the downstream differential genes regulated by TrkB are mainly involved in atypical hemolytic uremic syndrome, hematologic disease, meningococcal disease, lung cancer, susceptibility, asthma, and other diseases. The PPI network diagram results showed 7 hub genes, and then, we used GO analysis and KEGG enrichment analysis to see the biological process, cell component, molecular functions, and biological pathways. Conclusion Gene chip technology was used to screen out the differential genes of TrkB epigenetic modification in the Hep-2 cell line, and seven key genes (ALDH1A1, SDR16C5, PIK3R1, PLCG2, IL2RG, PIK3CD, and SPARC) were further screened using bioinformatics technology.

[1]  D. Yudhanto,et al.  Risk factors and characteristics of laryngeal carcinoma in the developing region of Indonesia , 2021 .

[2]  C. R. Leemans,et al.  Head and neck squamous cell carcinoma , 2020, Nature Reviews Disease Primers.

[3]  C. Bohr,et al.  Routine restaging after primary non-surgical treatment of laryngeal squamous cell carcinoma—a review , 2020, Strahlentherapie und Onkologie.

[4]  V. Grégoire,et al.  Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Olsen,et al.  Astrocyte morphogenesis is dependent on BDNF signaling via astrocytic TrkB.T1 , 2019, eLife.

[6]  J. Schwartz,et al.  A subtype of oral, laryngeal, esophageal, and lung, squamous cell carcinoma with high levels of TrkB-T1 neurotrophin receptor mRNA , 2019, BMC Cancer.

[7]  J. Zhang,et al.  BDNF activates TrkB/PLCγ1 signaling pathway to promote proliferation and invasion of ovarian cancer cells through inhibition of apoptosis. , 2019, European review for medical and pharmacological sciences.

[8]  F. Penault-Llorca,et al.  Testing algorithm for identification of patients with TRK fusion cancer , 2019, Journal of Clinical Pathology.

[9]  J. Rodrigo,et al.  Oncological and functional outcomes of transoral laser surgery for laryngeal carcinoma , 2018, European Archives of Oto-Rhino-Laryngology.

[10]  R. Hayes,et al.  Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer , 2018, JAMA oncology.

[11]  P. Vatanasapt,et al.  Epidemiology of head and neck cancer in Thailand , 2018, Asia-Pacific journal of clinical oncology.

[12]  Brett A Miles,et al.  AHNS Series: Do you know your guidelines? Review of current knowledge on laryngeal cancer , 2018, Head & neck.

[13]  Yuan Yuan,et al.  Upregulation of the BDNF/TrKB pathway promotes epithelial-mesenchymal transition, as well as the migration and invasion of cervical cancer. , 2017, International journal of oncology.

[14]  F. Guo,et al.  MiR-1-3p inhibits cell proliferation and invasion by regulating BDNF-TrkB signaling pathway in bladder cancer. , 2018, Neoplasma.

[15]  Hyeonseok Ko,et al.  Delphinidin inhibits BDNF-induced migration and invasion in SKOV3 ovarian cancer cells. , 2017, Bioorganic & medicinal chemistry letters.

[16]  Chuan Liu,et al.  TrkB promotes laryngeal cancer metastasis via activation PI3K/AKT pathway , 2017, Oncotarget.

[17]  R. Verhaak,et al.  Targeting tyrosine receptor kinase B in gliomas. , 2017, Neuro-oncology.

[18]  J. McNamara,et al.  Autocrine BDNF–TrkB signalling within a single dendritic spine , 2016, Nature.

[19]  A. Fasunla,et al.  Malignant tumors of the larynx: Clinicopathologic profile and implication for late disease presentation , 2016, Nigerian medical journal : journal of the Nigeria Medical Association.

[20]  K. Harrington,et al.  Laryngeal cancer: United Kingdom National Multidisciplinary guidelines , 2016, The Journal of Laryngology & Otology.

[21]  Yue Zhao,et al.  Risk factors for late dysphagia after (chemo)radiotherapy for head and neck cancer: A systematic methodological review , 2016, Head & neck.

[22]  A. Forastiere,et al.  Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. , 2016, Mayo Clinic proceedings.

[23]  A. Sartore-Bianchi,et al.  NTRK gene fusions as novel targets of cancer therapy across multiple tumour types , 2016, ESMO Open.

[24]  X. Wan,et al.  Upregulation of TrkB Promotes Epithelial-Mesenchymal Transition and Anoikis Resistance in Endometrial Carcinoma , 2013, PloS one.